CD33 and acute myeloid leukemia: They also point to the key role that chemotherapy-sensitive lymphocytes play in the therapeutic response to M2T-CD33, with the caveat that lymphodepleting chemotherapy drugs are likely to dampen the anti-AML efficacy of the immunotherapy.